目的：通过回顾性病例分析，评估DC-CIK细胞联合EGFR-酪氨酸激酶抑制剂(tyrosine kinase inhibitor, TKI)厄洛替尼或吉非替尼治疗EGFR突变阳性的进展期非小细胞肺癌（non-small cell lung cancer, NSCLC）患者的疗效和安全性。方法：所有入选的34例患者均确诊为EGFR突变阳性的进展期NSCLC，接受每日厄洛替尼150 mg或吉非替尼250 mg治疗，其中17例患者联合DC-CIK细胞治疗。分析比较 DC-CIK细胞联合用药组与单药组的疗效，以及外周血CD3+、CD4+和CD8+T细胞亚群的变化。结果：联合用药组7例患者（41.2%）获得PR，8例患者（47.1%）获得SD，2例患者（11.8%）出现疾病进展，客观缓解率为41.2%，疾病控制率为88.2%；联合用药组患者腹泻发生率明显低于单药治疗组（P<0.05）。单药组患者外周血CD3+、CD4+、CD8+细胞比例较治疗前无明显改善（P>0.05），EGFR-TKI联合DC-CIK组CD3+、CD4+T细胞比例较治疗前有所升高（P<005）、CD8较治疗前有所下降（P<0.05）。结论： DC-CIK细胞联合厄洛替尼或吉非替尼治疗EGFR突变阳性的进展期NSCLC患者具有良好的疗效，联合用药组患者T细胞免疫状态明显改善且不良反应可以耐受。

Objective:To evaluate efficacy and safety of DC-CIK cell combined with EGFR-TKI (tyrosine kinase inhibitor), erlotinib or gefitinib, treatment for progressive non-small cell lung cancer (NSCLC) patients with EGFR-mutation positive through a retrospective analysis of the patients. Methods: All of selected 34 patients were pathologically diagnosed as progressive NSCLC with EGFR-mutation positive, and treated with erlotinib (150 mg/d) or gefitinib (250 mg/d). Among them, 17 cases accepted the combined DC-CIK cell treatment. Curative effect and changes of peripheral blood CD3+, CD4+ and CD8+ T cell subsets were compared between the combined treatment and mono-drug groups. Results: In the combined treatment group, 7 patients (41.2%) had achieved PR, 8 patients (47.1%) achieved SD, and 2 patients (11.8%) emerged disease progress. Objective remission rate was 41.2%, and disease control rate 88.2%. Incidence of diarrhea in the combined treatment group, was obviously lower than that in the mono-drug group (P<0.05). Peripheral blood CD3+, CD4+ and CD8+ T cell subsets didn’t show any obvious changes before and after the treatment in the mono-drug group. However, in the combined treatment group after the treatment peripheral blood CD3+ and CD4+ T cell subsets were significantly increased (P<0.05) and peripheral blood CD8+ T cell subset decreased (P<0.05). Conclusion: The treatment of DC-CIK cell combined with erlotinib or gefitinib for progressive NSCLC patients with EGFR mutation positive had good efficacy. T cell immune status of the patients in the combined treatment group was significantly improved and adverse reactions tolerable.

辽宁省科技攻关计划课题资助项目（No. 2013225220）